Breaking News Instant updates and real-time market news.

EXEL

Exelixis

$19.77

-0.85 (-4.12%)

, ZYNE

Zynerba

$10.59

-0.37 (-3.38%)

07:35
08/13/19
08/13
07:35
08/13/19
07:35

Unusual call flow in option market yesterday

Notable call activity was cited Monday in Exelixis (EXEL) and Zynerba (ZYNE).

EXEL

Exelixis

$19.77

-0.85 (-4.12%)

ZYNE

Zynerba

$10.59

-0.37 (-3.38%)

  • 09

    Sep

EXEL Exelixis
$19.77

-0.85 (-4.12%)

06/17/19
STFL
06/17/19
NO CHANGE
STFL
Stifel would be surprised if another suitor tries to outbid Pfizer for Array
After Pfizer (PFE) announced an agreement to acquire Array BioPharma (ARRY) for $48 per share in cash, Stifel analyst Stephen Willey said he views the deal as a "fitting," "logical" and "appropriate" conclusion for Array shareholders and he would be "very surprised" if another suitor tried to compete with a higher priced offer. He believes a "very fair valuation" is implied by the $11.4B price Pfizer has agreed to pay, Willey added. He also sees the deal announcement providing a tailwind for the sector, specifically for small-to-mid cap oncology companies that are "perceived to have achieved some meaningful level of de-risking." As examples, he offers Exelixis (EXEL) and Blueprint Medicines (BPMC), though Willey added that a potentially shortened exclusivity runway could make a deal for Exelixis "a bit harder for a strategic to rationalize."
06/18/19
RHCO
06/18/19
DOWNGRADE
Target $48
RHCO
Hold
Array BioPharma downgraded to Hold from Buy at SunTrust
SunTrust analyst Peter Lawson downgraded Array BioPharma (ARRY) to Hold but raised his price target to $48 from $32 after the company announced that it is being acquired by Pfizer (PFE) at that price. The analyst notes that the 79% premium to the company's last closing price looks like a "fair valuation" based on his analysis of past comps and his M&A valuation model. Lawson adds that the the deal is "encouraging" within the biotech space with positive implications for other potential acquisition targets such as Agios Pharmaceuticals (AGIO) and Mirati herapeutics (MRTX) along with companies with strong chemistry such Incyte Corporation (INCY) and Exelixis (EXEL).
06/21/19
WBLR
06/21/19
NO CHANGE
WBLR
Outperform
William Blair an 'aggressive' buyer of Exelixis on weakness from clinical miss
William Blair analyst Andy Hsieh is an "aggressive" buyer of Exelixis (EXEL) shares on weakness after the company's partner Roche (RHHBY) informed the company that the Phase III IMspire170 trial, which assesses the safety and efficacy of the combination of Cotellic and Tecentriq, did not meet the primary endpoint of progression-free survival in treatment-naive melanoma. Hsieh says that while the news is disappointing, he reiterates that his bullish thesis resides in Exelixis's growth potential, driven by the Cabometyx franchise. As a result, the melanoma clinical setback does not impact the analyst's stock outlook. Further, he points out that he and the Street have not modeled revenue contribution from the IMspire170 study. Hsieh keeps an Outperform rating on Exelixis.
07/15/19
PIPR
07/15/19
NO CHANGE
PIPR
Exelixis trial updates 'encouraging,' says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff reiterated an Overweight rating and $45 price target on Exelixis, saying he is "confident" in CABO growth with net product sales forcast of $200M in Q2, $842M for FY19, and $1.08B in FY20. The analyst's note, titled Cabometyx I-O Combo Opportunity Grows in Phase Ib COSMIC-021 Study,' comes after the company announced new protocol updates to Phase Ib COSMIC-021 trial of Cabometyx + Tecentriq, which were spurred by "encouraging early efficacy and safety data in advanced NSCLC and mCRPC cohorts."
ZYNE Zynerba
$10.59

-0.37 (-3.38%)

05/08/19
05/08/19
NO CHANGE

Zynerba reports Q1 EPS (47c), consensus (49c)
05/31/19
HCWC
05/31/19
NO CHANGE
Target $23
HCWC
Buy
Zynerba remains 'potentially dramatically undervalued,' says H.C. Wainwright
H.C. Wainwright analyst Oren Livnat says that even with the stock up 324% year-to-date, shares of Zynerba Pharmaceuticals remain "potentially dramatically undervalued." The analyst continues to entirely value the company on the opportunity in Fragile X Syndrome, and he expects Zynerba to soon announce CONNECT-FX Phase 3 enrollment completion which would put the company on track for transformative topline data in Q4. He projects peak U.S. sales of $700M and keeps a Buy rating on the shares with a $23 price target.
05/31/19
CANT
05/31/19
NO CHANGE
Target $22
CANT
Overweight
Zynerba price target raised to $22 from $12 at Cantor Fitzgerald
Cantor Fitzgerald analyst Charles Duncan raised his price target for Zynerba Pharmaceuticals to $22 from $12 citing his due diligence on Fragile X and the anecdotal use of CBD to alleviate symptoms for this and other pediatric orphan neurodevelopmental disorders. The analyst says he's also seen broadening interest in the medical cannabis space with the emergence of exchange traded funds possibly driving demand for the shares. Duncan reiterates an Overweight rating on Zynerba.
06/10/19
PIPR
06/10/19
NO CHANGE
PIPR
Cannabis regulation could become top 2020 election issue, says Piper Jaffray
After Washington D.C. lobbyist Michael Esposito, who also works closely with President Trump's administration, spoke at his firm's conference, Piper Jaffray analyst Michael Lavery believes cannabis regulation could become a top 2020 election issue. By supporting cannabis, Trump may be able to incrementally broaden his appeal with swing voters without alienating his base, Esposito tells investors in a research note. Though Trump has indicated his willingness to support the STATES Act, his enthusiasm could depend on whether or not Elizabeth Warren, author of the bill, is his opponent, adds the analyst in a note titled "Handicapping US Legalization Outlook: Politics Are Complicated." And while Senate Majority Leader Mitch McConnell is a roadblock for legislation in the Senate, Trump could use executive orders between now and the election to show support for the industry, potentially relating to cannabis banking or medical research, says Lavery. The analyst has Overweight ratings on both Canopy Growth (CGC) and Tilray (TLRY). Other names in the space include Aphria (APHA), Aurora Cannabis (ACB), CV Sciences (CVSI), CannTrust Holdings (CNTTF), Cronos Group (CRON), General Cannabis (CANN), India Globalization Capital (IGC), MediPharm Labs (MLCPF) and Zynerba (ZYNE).

TODAY'S FREE FLY STORIES

LLY

Eli Lilly

$111.63

0.2 (0.18%)

21:03
08/22/19
08/22
21:03
08/22/19
21:03
Hot Stocks
Arbitration panel rules in favor of Eli Lilly in Adocia IP claim »

A Chicago-based…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

  • 16

    Sep

  • 02

    Oct

  • 23

    Oct

FL

Foot Locker

$42.00

2.24 (5.63%)

, HIBB

Hibbett Sports

$17.01

0.845 (5.23%)

20:25
08/22/19
08/22
20:25
08/22/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

FL

Foot Locker

$42.00

2.24 (5.63%)

HIBB

Hibbett Sports

$17.01

0.845 (5.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

  • 23

    Aug

  • 19

    Sep

  • 25

    Sep

RGR

Sturm, Ruger

$41.48

0.69 (1.69%)

, AOBC

American Outdoor Brands

$7.69

-0.01 (-0.13%)

19:40
08/22/19
08/22
19:40
08/22/19
19:40
Hot Stocks
Trump 'hopeful' to work with Congress on' legislation addressing mass shootings »

President Donald Trump…

RGR

Sturm, Ruger

$41.48

0.69 (1.69%)

AOBC

American Outdoor Brands

$7.69

-0.01 (-0.13%)

VSTO

Vista Outdoor

$5.33

0.26 (5.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Aug

  • 10

    Sep

  • 19

    Sep

TOT

Total

$48.98

-0.18 (-0.37%)

19:16
08/22/19
08/22
19:16
08/22/19
19:16
Downgrade
Total rating change at Citi »

Total downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KMPR

Kemper

$75.42

0.48 (0.64%)

19:14
08/22/19
08/22
19:14
08/22/19
19:14
Downgrade
Kemper rating change at William Blair »

Kemper downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

  • 10

    Sep

  • 11

    Sep

CRM

Salesforce

$148.26

0.86 (0.58%)

, INTU

Intuit

$276.05

-0.29 (-0.10%)

18:52
08/22/19
08/22
18:52
08/22/19
18:52
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: …

CRM

Salesforce

$148.26

0.86 (0.58%)

INTU

Intuit

$276.05

-0.29 (-0.10%)

PVTL

Pivotal Software

$13.69

0.01 (0.07%)

CBLK

Carbon Black

$24.52

1.77 (7.78%)

HPQ

HP Inc.

$18.91

-0.04 (-0.21%)

RAVN

Raven

$31.36

-0.87 (-2.70%)

VMW

VMware

$148.15

0.11 (0.07%)

ROST

Ross Stores

$107.31

1.63 (1.54%)

GPS

Gap

$17.75

0.79 (4.66%)

HAS

Hasbro

$114.35

-1.06 (-0.92%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 22

    Aug

  • 22

    Aug

  • 22

    Aug

  • 22

    Aug

  • 22

    Aug

  • 22

    Aug

  • 28

    Aug

  • 28

    Aug

  • 04

    Sep

  • 10

    Sep

  • 25

    Sep

  • 10

    Oct

  • 27

    Oct

  • 12

    Dec

  • 16

    Dec

TLND

Talend

$39.24

0.12 (0.31%)

18:45
08/22/19
08/22
18:45
08/22/19
18:45
Hot Stocks
Talend CEO: We solve the first mile in the data journey »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$354.47

14.44 (4.25%)

18:40
08/22/19
08/22
18:40
08/22/19
18:40
Periodicals
FAA intends to test Boeing MAX software on newer pilots, Reuters says »

Next month, the FAA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Sep

DB

Deutsche Bank

$7.17

0.155 (2.21%)

18:32
08/22/19
08/22
18:32
08/22/19
18:32
Periodicals
Deutsche Bank to pay $16M to settle corruption charges with SEC, Reuters says »

The SEC said that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$292.36

-0.04 (-0.01%)

18:28
08/22/19
08/22
18:28
08/22/19
18:28
Periodicals
Kudlow says U.S., Chinese negotiators held productive trade talks, Reuters says »

White House economic…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$292.36

-0.04 (-0.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$1,188.53

-2.26 (-0.19%)

, GOOGL

Alphabet Class A

$1,190.41

0.15 (0.01%)

18:25
08/22/19
08/22
18:25
08/22/19
18:25
Hot Stocks
Google disabled 210 YouTube channels related to ongoing Hong Kong protests »

Google (GOOG) said in a…

GOOG

Alphabet

$1,188.53

-2.26 (-0.19%)

GOOGL

Alphabet Class A

$1,190.41

0.15 (0.01%)

FB

Facebook

$182.08

-1.48 (-0.81%)

TWTR

Twitter

$42.17

-0.63 (-1.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Sep

  • 24

    Sep

  • 27

    Oct

NUAN

Nuance

$17.31

-0.14 (-0.80%)

18:24
08/22/19
08/22
18:24
08/22/19
18:24
Syndicate
Nuance files Form 10 registration statement for planned spin-off of Cerence »

Nuance Communications…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRM

Salesforce

$148.26

0.86 (0.58%)

18:23
08/22/19
08/22
18:23
08/22/19
18:23
Hot Stocks
Salesforce co-CEO: We had a very strong second quarter »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 28

    Aug

  • 28

    Aug

  • 12

    Dec

  • 16

    Dec

RVLT

Revolution Lighting

$0.34

-0.0124 (-3.57%)

18:10
08/22/19
08/22
18:10
08/22/19
18:10
Hot Stocks
Revolution Lighting discloses additional delisting determination from Nasdaq »

Revolution Lighting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IBKC

Iberiabank

$70.16

-0.38 (-0.54%)

18:05
08/22/19
08/22
18:05
08/22/19
18:05
Hot Stocks
Iberiabank CEO Daryl Byrd sells over $840K in company shares »

Iberiabank CEO Daryl Byrd…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

RMNI

Rimini Street

$4.77

-0.11 (-2.25%)

, ORCL

Oracle

$53.18

-0.08 (-0.15%)

18:02
08/22/19
08/22
18:02
08/22/19
18:02
Hot Stocks
San Fang Chemical switches to Rimini Street support for Oracle EBS »

Rimini Street (RMNI)…

RMNI

Rimini Street

$4.77

-0.11 (-2.25%)

ORCL

Oracle

$53.18

-0.08 (-0.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRM

Salesforce

$148.26

0.86 (0.58%)

18:01
08/22/19
08/22
18:01
08/22/19
18:01
Hot Stocks
Salesforce says Customer 360 will be huge growth driver over next decade »

Says: Momentum in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 28

    Aug

  • 28

    Aug

  • 12

    Dec

  • 16

    Dec

AAC

AAC Holdings

$0.60

-0.0327 (-5.17%)

17:57
08/22/19
08/22
17:57
08/22/19
17:57
Hot Stocks
AAC Holdings discloses NYSE listing notice »

AAC Holdings announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

17:32
08/22/19
08/22
17:32
08/22/19
17:32
General news
Fed Balance Sheet Level data reported »

Week of 8/21 Fed Balance…

HPQ

HP Inc.

$18.91

-0.04 (-0.21%)

17:30
08/22/19
08/22
17:30
08/22/19
17:30
Hot Stocks
HP Inc. says notebooks accounted for 39% of revenue in Q3 »

Says supplies category…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 10

    Sep

17:28
08/22/19
08/22
17:28
08/22/19
17:28
General news
Money Supply M2 Weekly Change data reported »

Week of 8/12 Money Supply…

TRPX

Therapix Biosciences

$2.35

(0.00%)

17:27
08/22/19
08/22
17:27
08/22/19
17:27
Syndicate
Breaking Syndicate news story on Therapix Biosciences »

Therapix Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLD

SPDR Gold Shares

$141.38

-0.36 (-0.25%)

17:26
08/22/19
08/22
17:26
08/22/19
17:26
Hot Stocks
SPDR Gold Shares holdings rise to 854.84MT to 851.91MT »

This is the third…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VMW

VMware

$148.15

0.11 (0.07%)

17:19
08/22/19
08/22
17:19
08/22/19
17:19
Earnings
VMware sees Q3 adjusted EPS $1.42, consensus $1.57 »

Sees Q3 revenue growth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 10

    Sep

  • 10

    Oct

CRWD

Crowdstrike

$93.04

-3.5 (-3.63%)

, CBLK

Carbon Black

$24.52

1.77 (7.78%)

17:14
08/22/19
08/22
17:14
08/22/19
17:14
Hot Stocks
Crowdstrike lower after Carbon Black acquisition »

Shares of cybersecurity…

CRWD

Crowdstrike

$93.04

-3.5 (-3.63%)

CBLK

Carbon Black

$24.52

1.77 (7.78%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.